Phathom Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary

Phathom Pharmaceuticals

30/07/2026 17:38

Phathom Pharmaceuticals Inc PHAT.OQ reported a quarterly adjusted loss of 21 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of $-1.05.  The mean expectation of ten analysts for the quarter was for a loss of 25 cents per share. Wall Street expected results to range from -37 cents to -18 cents per share.
Revenue rose 88% to $74.27 million from a year ago; analysts expected $72.79 million. 
Phathom Pharmaceuticals Inc's reported EPS for the quarter was a loss of 21 cents​.
The company reported a quarterly loss of $17.58 million.
Phathom Pharmaceuticals Inc shares had risen by 7.3% this quarter and lost 29.8% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had fallen by about 13.8% in the last three months.​ 
In the last 30 days, two analysts negatively revised earnings estimates
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy" 
Wall Street's median 12-month price target for Phathom Pharmaceuticals Inc is $25.50, about 54.4% above its last closing price of $11.64
This summary was machine generated from LSEG data July 30 at 04:38 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
-0.25
-0.21
Beat
Mar. 31 2026 
-0.32
-0.37
Missed
Dec. 31 2025 
-0.38
-0.29
Beat
Sep. 30 2025 
-0.54
-0.41
Beat